Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis - Wikidata - wikimedia - TriplyDB

Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis

Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis

http://www.wikidata.org/entity/Q35715738

about

Key fibrogenic mediators: old players. Renin–angiotensin system Fibrosis Related Inflammatory Mediators: Role of the IL-10 Cytokine Family Micromanaging abdominal aortic aneurysms Role of regulatory micro RNAs in type 2 diabetes mellitus-related inflammation Recent developments in myofibroblast biology: paradigms for connective tissue remodeling MicroRNAs in Diabetic Kidney Disease MicroRNAs in fibrosis: opportunities and challenges Mini-review: emerging roles of microRNAs in the pathophysiology of renal diseases Systemic Delivery of scAAV8-Encoded MiR-29a Ameliorates Hepatic Fibrosis in Carbon Tetrachloride-Treated Mice Systems biology combining human- and animal-data miRNA and mRNA data identifies new targets in ureteropelvic junction obstruction microRNA in the development of diabetic complications.MiRNAs in kidney transplantation: potential role as new biomarkers.GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression.Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis.Downregulation of miR-205 modulates cell susceptibility to oxidative and endoplasmic reticulum stresses in renal tubular cells.MicroRNA-29 overexpression by adeno-associated virus suppresses fibrosis and restores muscle function in combination with micro-dystrophin Altered expression of circulating microRNA in plasma of patients with primary osteoarthritis and in silico analysis of their pathways MiRNA-29c regulates the expression of inflammatory cytokines in diabetic nephropathy by targeting tristetraprolin.European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS).Post-transcriptional regulation in osteoblasts using localized delivery of miR-29a inhibitor from nanofibers to enhance extracellular matrix deposition.MicroRNA-29a promotion of nephrin acetylation ameliorates hyperglycemia-induced podocyte dysfunction.The role of microRNAs in diabetic nephropathy.Distinct mesenchymal alterations in N-cadherin and E-cadherin positive primary renal epithelial cells Functional implications of microRNA-215 in TGF-β1-induced phenotypic transition of mesangial cells by targeting CTNNBIP1.MicroRNAs and their applications in kidney diseases MiR-29a reduces TIMP-1 production by dermal fibroblasts via targeting TGF-β activated kinase 1 binding protein 1, implications for systemic sclerosis Transforming growth factor-β induces microRNA-29b to promote murine alveolar macrophage dysfunction after bone marrow transplantation The modified selenenyl amide, M-hydroxy ebselen, attenuates diabetic nephropathy and diabetes-associated atherosclerosis in ApoE/GPx1 double knockout mice MicroRNA mimicry blocks pulmonary fibrosis.Social isolation impairs oral palatal wound healing in sprague-dawley rats: a role for miR-29 and miR-203 via VEGF suppression.Urinary miR-29 correlates with albuminuria and carotid intima-media thickness in type 2 diabetes patients.Bone morphogenetic protein signaling protects against cerulein-induced pancreatic fibrosis.Contribution of microRNA to pathological fibrosis in cardio-renal syndrome: impact of uremic toxins Epigenetic mechanisms of endothelial dysfunction in type 2 diabetes.A Pilot Study Identifying a Set of microRNAs As Precise Diagnostic Biomarkers of Acute Kidney Injury MicroRNAs, fibrotic remodeling, and aortic aneurysms.Pathophysiological role of microRNA-29 in pancreatic cancer stroma Different regulation of miR-29a-3p in glomeruli and tubules in an experimental model of angiotensin II-dependent hypertension: potential role in renal fibrosis.Differential microRNA expression in the serum of patients with nephrotic syndrome and clinical correlation analysis.Circulating TGF-β1-Regulated miRNAs and the Risk of Rapid Progression to ESRD in Type 1 Diabetes.

P2860

Q26796631-297B97D1-A6F6-4A53-8FB5-89E766FF9E23 Q26801150-F49D1F35-9AA0-4CB1-8757-C7EF3EE5959E Q26823361-BA7545E5-D8B8-410B-AE79-60B1A2D3DE60 Q26830676-2A5AF6D9-379B-4EF1-8F49-9EB0484B87A2 Q26863751-AED1C089-DECA-4E55-934C-5ECC5A5BEE33 Q27002171-B7C709E3-280E-4C94-BB8C-D353853D8B21 Q28067380-7A2A1EEB-501C-48AC-AE0D-E6D153274209 Q28354033-50DD1973-4271-427C-B4D6-7A3652F16617 Q28546811-D3999D19-94F7-42A7-8728-DBAB6A48FEDB Q30253062-6DA82E05-ED86-48C7-875E-C76C57668190 Q30353835-C4122DA9-B4C2-4A3F-84B1-5EAC46EC0FA6 Q30456341-4249F0B3-C8EC-4CDE-8935-A11A7CD6641C Q30540007-C78AD51D-7BA9-4B58-962B-922257143ED0 Q30541198-86BE96FC-A9E6-4BD0-86AE-D93397AE4224 Q31080106-9D75EF39-8249-4CAC-9E76-2D263E2D105B Q33631076-73E97C1C-C5CF-4BF3-B471-DE0F1DA5F561 Q33716714-4CA38988-8FEB-43B1-B98E-9E2EE2B4C122 Q33725787-956F55DC-D4E4-4C79-A3B6-7C7625C923B2 Q33761211-5C33C069-F363-499F-971B-3075F1BCEF25 Q33965312-B5AEF42B-890D-4722-94B7-A93E52D4F400 Q33974555-96E07F30-7A4F-4F2C-92FB-8243D87ADFAD Q34195411-6803716B-6BC5-4C4F-93C8-F59253A86844 Q34389693-70EE025D-6925-4EAA-AA5C-559746B5929A Q34648147-CFCB9063-4855-483A-8013-BF2B578BE991 Q34696427-A1E9A344-5E31-4063-8B7C-D4A5E90DCA6A Q34790405-D881FF14-3C12-409E-AF86-7D29DA7EF59A Q34801214-3C74F5A7-6E9B-4779-9E0D-E6C0DF18AF92 Q34853356-F7F4E6BF-C621-4EF0-B2AF-F3FE2320624E Q34880449-0E49DC63-465D-4227-B911-4A30F3A01B5E Q34951617-13D1C54E-11ED-456D-A8E1-2852913C53D0 Q35070398-CF60E47F-7D1D-4B1A-817A-C8E66429B8EC Q35106679-6084D4BF-F32E-4723-80D2-D0B5398AC2FF Q35588665-3DB6CCF3-9C55-4C00-B930-2DB1F1CEA86F Q35645997-7D0F895C-FE1E-4E28-AB15-DE3BF2C3D47D Q35665062-531E2334-5DBE-4ED6-AB67-1BA7FF3F6E5B Q35699046-FE90936D-7E1A-4F99-B2F6-09B804AE48D4 Q35765000-982C697C-F841-481F-9CF2-C08EB897A936 Q35877447-81FF5029-9181-44AF-A814-53CD8A230F4B Q35919405-02745B32-4A04-4477-BA77-B3A62F93344D Q35973844-A6804C56-ACCD-4F0C-BA26-693F19DF9AD3

P2860

Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis

http://www.wikidata.org/entity/Q35715738

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Suppression of microRNA-29 exp ...... expression and renal fibrosis

@ast

Suppression of microRNA-29 exp ...... expression and renal fibrosis

@en

type

label

Suppression of microRNA-29 exp ...... expression and renal fibrosis

@ast

Suppression of microRNA-29 exp ...... expression and renal fibrosis

@en

prefLabel

Suppression of microRNA-29 exp ...... expression and renal fibrosis

@ast

Suppression of microRNA-29 exp ...... expression and renal fibrosis

@en

P1433

Q35715738-14C11B62-3B11-4319-8C6B-F0B7CB693D23

P1476

Q35715738-76F9637D-725A-4226-9591-05B1B91CFDB1

P2093

Q35715738-0F1503A2-8F25-4532-AF7C-D79492492F2F

Q35715738-1B36B5F8-EAD9-462F-80F7-8F57F78D3782

Q35715738-265B3260-7043-4BF6-8E8B-A0425FBEFC30

Q35715738-3385C8B7-A9E7-42CD-B707-2B218419196E

Q35715738-355B2A2E-681F-4B0F-B605-34207FCCB5C6

Q35715738-6919C286-FDDE-4A6B-A063-46B56BFC737B

Q35715738-6EC1E935-85DA-4089-9CFD-6E0B400A21F5

Q35715738-883CD2B5-3BE1-44D4-B8EB-4C2E43E1F1A8

Q35715738-A6CF04F9-8FDE-4271-A9F5-E07695AC7F55

Q35715738-C0AEA75B-5FF3-4A12-8E0C-B20A74E16D6B

P2860

Q35715738-0436A57C-6807-4441-A997-DA47788DD645

Q35715738-04F1AF5C-B3DF-447B-B62C-0918576B1A0F

Q35715738-0AF84430-8674-430D-82BD-2478C9207363

Q35715738-12453F43-EC89-4D38-BCE0-998055D40748

Q35715738-1CA016D2-FC3B-4763-BC84-4A7DA6B2C6F9

Q35715738-1D198C42-49AD-4FAD-8907-773B7C908B9E

Q35715738-1DDF65C0-ABAE-4AF1-8D59-F26017443B43

Q35715738-20431D30-2980-49EC-98A5-8AF1882673B3

Q35715738-346E56B4-6027-4E0C-93D0-69BD32EBBBA9

Q35715738-36A96620-0884-40DC-91D6-B0CAF1BD984B

P304

Q35715738-80D96906-0F57-4E3B-A965-57C2BF352252

P31

Q35715738-3E76C4D4-9C24-4EB7-B839-9CA578EAA9AA

P356

Q35715738-4CAD23AB-F742-4799-A977-5E4652841549

P433

Q35715738-022759CB-0340-4A27-8882-417ED9E87DDA

P478

Q35715738-DFAB4ABB-4041-4E0E-AF42-3FAEE339F7AE

P577

Q35715738-35553B2D-1B03-4F14-979D-76DE9EEDC7E6

P5875

Q35715738-D78B439E-BB90-46C0-BAFD-479F1DC0CF0C

P698

Q35715738-A5702853-6C7D-46DC-9F40-65D46D53B355

P921

Q35715738-33C7D40F-EAEC-4461-8B50-9EBD6D497323

P932

Q35715738-618C213A-E0F1-4D7C-8DD6-0E4D08CF748E

P356

P1433

Journal of the American Society of Nephrology

P1476

Suppression of microRNA-29 exp ...... expression and renal fibrosis

@en

P2093

Bei Xu

http://www.w3.org/2001/XMLSchema#string

Bo Wang

http://www.w3.org/2001/XMLSchema#string

Catherine E Winbanks

http://www.w3.org/2001/XMLSchema#string

Karin Jandeleit-Dahm

http://www.w3.org/2001/XMLSchema#string

Mark E Cooper

http://www.w3.org/2001/XMLSchema#string

Merlin Thomas

http://www.w3.org/2001/XMLSchema#string

Michal Herman-Edelstein

http://www.w3.org/2001/XMLSchema#string

Paul Gregorevic

http://www.w3.org/2001/XMLSchema#string

Philip Koh

http://www.w3.org/2001/XMLSchema#string

Phillip Kantharidis

http://www.w3.org/2001/XMLSchema#string

P2860

The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2

A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells

Deadenylation is a widespread effect of miRNA regulation

The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1

MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins.

Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin

Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE)

RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease

Control of translation and mRNA degradation by miRNAs and siRNAs

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

P304

252-265

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2011010055

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51808134

http://www.w3.org/2001/XMLSchema#string

P698

22095944

http://www.w3.org/2001/XMLSchema#string

P921

P932

3269175

http://www.w3.org/2001/XMLSchema#string